Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Jun;72(6):838-849.
doi: 10.1002/acr.23901. Epub 2020 May 19.

Prevalence of Giant Cell Arteritis Relapse in Patients Treated With Glucocorticoids: A Meta-Analysis

Sabine Mainbourg  1 , Alexandra Addario  2 , Maxime Samson  3 , Xavier Puéchal  4 , Mathilde François  1 , Stéphane Durupt  2 , François Gueyffier  2 , Michel Cucherat  2 , Isabelle Durieu  1 , Quitterie Reynaud  1 , Jean-Christophe Lega  1
Affiliations
Meta-Analysis

Prevalence of Giant Cell Arteritis Relapse in Patients Treated With Glucocorticoids: A Meta-Analysis

Sabine Mainbourg et al. Arthritis Care Res (Hoboken). 2020 Jun.

Abstract

Objective: The relapse rate of patients with giant cell arteritis (GCA) treated with glucocorticoids (GCs) alone varied widely in observational series and randomized controlled trials (RCTs). The purpose of this systematic review was to evaluate the prevalence of relapse and predisposing factors in patients receiving GCs alone.

Methods: We searched Medline up to December 2017. The prevalence of relapse was pooled using a random-effects model.

Results: A total of 34 studies (2,505 patients), comprising 8 RCTs, were included. The overall prevalence of relapse was 47.2% (95% confidence interval 40.0, 54.3) with a high heterogeneity (I2 = 93%). Prevalence of relapse was significantly higher for patients included in an RCT compared to those included in an observational study (P < 0.0001), but was not significantly different according to design (P = 0.06). The relapse rate was associated with year of publication (34 studies, rate increase of 8.3% for 1 decade; P < 0.0001) and with shorter GC regimens (17 studies, rate decrease of 1.7% for 1 additional month; P < 0.001), the duration of scheduled GC therapy being shorter in RCTs (12.8 months) compared to observational studies (28.8 months). The effective duration of GC therapy (P = 0.23), initial GC dose (P = 0.49), duration of follow-up (P = 0.14), sex (P = 0.29), and age (P = 0.43) were not associated with the prevalence of relapse.

Conclusion: GCA relapses occur in half of patients and without improvement across decades in patients receiving GC alone, and the relapse rate is more related to short duration of GC administration than to the initial dose at induction. These results advocate for trial design with at least 12 months of GC therapy.

PubMed Disclaimer

References

    1. Boes CJ. Bayard Horton's clinicopathological description of giant cell (temporal) arteritis. Cephalalgia 2007;27:68-75.
    1. Catanoso M, Macchioni P, Boiardi L, Muratore F, Restuccia G, Cavazza A, et al. Incidence, prevalence, and survival of biopsy-proven giant cell arteritis in Northern Italy during a 26-year period. Arthritis Care Res (Hoboken) 2017;69:430-38.
    1. Li L, Neogi T, Jick S. Mortality in patients with giant cell arteritis: a cohort study in UK primary care. Arthritis Care Res (Hoboken) 2018;70:1251-6.
    1. Hill CL, Black RJ, Nossent JC, Ruediger C, Nguyen L, Ninan JV, et al. Risk of mortality in patients with giant cell arteritis: a systematic review and meta-analysis. Semin Arthritis Rheum 2017;46:513-9.
    1. Bienvenu B, Ly KH, Lambert M, Agard C, André M, Benhamou Y, et al. Management of giant cell arteritis: recommendations of the French Study Group for Large Vessel Vasculitis (GEFA). Rev Med Interne 2016;37:154-65.

Publication types

Substances

LinkOut - more resources